|

Adjuvant therapy Clinical Trials

4 actively recruiting trials across 1 location

▲ +1 trial since August 2026

Also known as: Standard of Care

Pipeline

Phase 2: 3Phase 3: 1

Top Sponsors

  • Fudan University2
  • Qilu Hospital of Shandong University1
  • Philogen S.p.A.1

Indications

  • Cancer4
  • Melanoma Stage IIID1
  • Melanoma Stage IIIC1
  • Melanoma Stage IIIB1
  • Tislelizumab1

Other3 trials

Dynamic Risk-adapted EBV-DNA and MRI-guided De-concurrent Chemotherapy in Nasopharyngeal Carcinoma
Phase 2
Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study
Phase 2
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
Phase 2

Phoenix, Arizona1 trial

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients

Mayo Clinic Hospital

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.